Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10099814 | 0.87 | ITGB3 (0.54) | LCK | |
| SCHEMBL11864242 | 0.87 | LCK (0.68) | LCKHDAC1HDAC6ALDH1A1NPSR1 | |
| SCHEMBL6139811 | 0.86 | LCK (0.67) | LCKHDAC1HDAC6ALDH1A1NPSR1 | |
| SCHEMBL10099813 | 0.86 | CA1 (0.56) | LCK | |
| SCHEMBL19682099 | 0.83 | MAPT (0.62) | LCKHDAC1HDAC6ALDH1A1 | |
| SCHEMBL19682098 | 0.83 | MAPT (0.62) | LCKHDAC1HDAC6ALDH1A1 | |
| SCHEMBL6267583 | 0.83 | LCK (0.70) | LCKHDAC1HDAC6ALDH1A1NPSR1 | |
| SCHEMBL11348361 | 0.82 | HDAC1 (0.65) | HDAC1HDAC6 | |
| SCHEMBL11348366 | 0.82 | HDAC1 (0.65) | HDAC1HDAC6 | |
| SCHEMBL10099867 | 0.82 | HDAC1 (0.52) | HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722923-B2 | Conjugates for treating neurodegenerative diseases and disorders | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2014-05-13 | — | — | US | disclosed |
| US-20120277310-A1 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | BAR-ILAN UNIVERSITY (IL) | 2012-11-01 | — | — | US | disclosed |
| US-8207369-B2 | Conjugates for treating neurodegenerative diseases and disorders | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2012-06-26 | — | — | US | disclosed |
| US-20110034553-A1 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277310-A1 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | SLC18A2, GABRB2, SLC6A13 | LCK 3607/4885HDAC1 2692/4885HDAC6 96/4885 |
| US-20110034553-A1 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | SLC18A2, SNCA, SLC6A13 | LCK 2796/4885HDAC1 3125/4885HDAC6 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.